Search

For now, the long-term trend remains up, and so do most of our Cabot Dividend Investor positions. Here’s what’s going on with each of them as we enter summer.

The bull market remains alive and well, and I continue to recommend that you be heavily invested in a diversified portfolio of stocks.

Last week’s recommendation was well-known Coca-Cola (a true value stock) while this week’s is a fast-growing company that’s never made a profit, but is expected to make bundles, someday. You know its name too!



As for our current portfolio, most trends are good, but we do need to sell one stock, just to keep the portfolio at twenty stocks. That’s a process that ensures we always own the best!

Yesterday three American professors, Eugene Fama, Robert Shiller and Lars Peter Hansen, won the 2013 Nobel Prize in economics for their research on asset price movement. The three don’t work together—to the contrary, they’ve actually developed some competing theories. One economist commented that the Nobel Prize committee’s decision to recognize all...

I’ve been traveling between New York and Boston frequently for over three years. The transportation options between the two have definitely improved since I moved here; now I can choose the Bolt Bus or the Megabus, both of which have WiFi and electrical outlets. But I’ve also taken the Fung...

Breaking news: Teenagers have stopped caring (as much) about brands and labels and are starting to shop based on savings and sales. Who ever thought we’d see this day? This week’s New York Times contained the story of how the recession has turned teenage shoppers, one of the most powerful spending groups, into penny pinchers. This, of course, has hurt some of the higher-priced teen shops, like Abercrombie & Fitch, while others, like A&F’s lower-priced sister Hollister, are benefiting from this change.

The U.S. has one of the best freight railroad systems and one of the worst passenger railroad systems.

Emerging market stocks aren’t doing all that well, but Chinese ADRs are showing considerable strength. That’s the bad-news/good-news summary of today’s commentary. And the theme continues in today’s issue, where we’re adding a stock that has been on a breakout run since the middle of May. Our timing wasn’t right when we took our first position in the stock in late 2017, but the recent rally is offering us a second chance, if we can get the timing right. For the tantalizing details, read on!

Today’s recommendation is a classic steelmaker that has great growth prospects as the U.S. economy speeds along and protectionist measures improve our country’s competitive position. Also, the stock is cheap, so downside risk is limited.

Here are two healthcare stocks that are currently undervalued and sell at bargain prices.

I’ve profiled 10 revolutionary stocks here, describing how each one has the potential to yield very large profits.

In a bit of a reversal, tech stocks gyrated and industrial stocks jumped this past week. In particular, energy and financial stocks led the way as the Dow closed above 32,000 for the first time. Tech company stalwarts rebounded a bit yesterday but have been stung by the sharp pullback.

While the vast majority of my research involves growth stocks, I do keep an eye out for potential turnaround situations. Why? Because historically, about one out of every five or six big winners will be a turnaround situation—especially in so-so economic times. (In the late 1990s, by contrast, almost all the big winners were growth stocks.) So, even though I never, ever (ever!) buy stocks and sectors that are in longer-term downtrends, I do keep an eye on them for signs that they’re turning higher. That leads me to energy and gold stocks.

The year’s first major bout of market volatility hit this week. It’s about time. I’m moving two of our stocks to Hold.

It has been a fabulous rally that has proven naysayers wrong. The S&P 500 is up about 15% YTD just before the midpoint. Stocks have also rallied more than 20% from the October low into a new bull market.

How much gas is left in the tank?

Inflation is falling and the Fed is almost done hiking rates. It is also looking less likely that there will be a recession this year. Investors are optimistic that we can get to the other side of this hiking cycle without too much pain.

It was another good week for Explorer recommendations led by ChargePoint (CHPT), up 17%, and Butterfly (BFLY), up another 8%.


Some of you will remember when George Gilder’s Wealth and Poverty hit the market in 1981 like a thunderclap. It was intellectual capital and political firepower for both the Reagan Revolution and a big bull market.



Mr. Gilder has been active ever since and has a new book out that I highly recommend, Life After Capitalism.

Prepare yourself for more ups and downs in our medtech & biotech stocks if this debate heats up. I’m not planning to step out of the space since I think this will pass and we can still do quite well with these types of stocks.

Small-cap MedTech stocks are a small subsector of the market that appear poised to outperform in the year ahead. Here are three that I like.

Ulta Salon (ULTA) has been recommended several times in Cabot newletters in recent months.

With this month’s new addition, I decided to go in a different direction then we have with previous recommendations. Instead of featuring another rapid-growth medical device or software stock, I’ve selected a consumer defensive stock in a very specialized industry and with a more modest growth profile. It’s the perfect summertime stock for a period in which many growth stocks are acting a little schizophrenic—especially for those investors who like getting out of the house for a bite to eat and a good beer or glass of wine.

The chances that the stock market will rise another 18% during the next 12 months or so are pretty good.